0.05Open0.05Pre Close0 Volume84 Open Interest17.00Strike Price0.00Turnover119.94%IV52.10%PremiumJan 17, 2025Expiry Date0.00Intrinsic Value100Multiplier14DDays to Expiry0.05Extrinsic Value100Contract SizeAmericanOptions Type0.0496Delta0.0389Gamma224.20Leverage Ratio-0.0093Theta0.0002Rho11.11Eff Leverage0.0022Vega
Omeros Stock Discussion
how long will the hold off volume before reaching above 30
Omeros’ Narsoplimab Meets its Pivotal Trial Primary Endpoint – Statistical Analysis Shows Survival Superiority Over External Control in Patients with TA-TMA
Omeros (OMER) announced successful results from its narsoplimab pivotal trial for treating transplant-associated thrombotic microangiopathy (TA-TMA). The primary statistical analysis showed that patients treated with narsoplimab had an over 3-fold reduction in mortality risk (hazard ratio = 0.32) compared to untreated p...
No comment yet